Summary

Other Scenarios:

Buyer: PRA International (PRAI) Last Price: 29.94 Market Cap.: 739.11M
Target: Penwest Pharmaceuticals (PPCO) Last Price: 8.55 Market Cap.: 200.03M

Lines of Business Summary:

Product Summary:

Overlap & Complementary Sectors

Sector Buyer Target # of Focused Companies
Healthcare 931
Biopharmaceuticals   377
Healthcare Services   153
Outsourced Services 69
Technology   1,039
Software   308

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Sample Products in Similar Lines of Business

Sample Products in Complementary Lines of Business
Buyer (Total: 11)
  • Early Development Services
  • PRA International Clinical Pharmacology Center
  • Global Medical And Safety Services
  • Clinical Trials Management Services
Target (Total: 12)
  • SyncroDose
  • Geminex
  • TIMERx
  • Gastroretentive Drug Delivery System
Buyer
  • Global Regulatory Affairs Group
  • Global Product Development Services
  • PRA Clinical Data Manager And Oracle Clinical
  • Flex DMS
Target
  • Nifedipine XL
  • PW2132 (Torsemide ER)
  • PW4110
  • PW4153

Business Relationship Summary:

Top Key Suppliers

Top Key Customers
Buyer (Total: 1)
  • ePlus Inc. (PLUS)
Target (Total: 2)
  • Mylan Inc. (MYL)
  • DRAXIS Health Inc. (USA) (DRAX)
Buyer (Total: 1)
  • Biomira Inc. (USA) (BIOM)
Target (Total: 4)
  • Mylan Inc. (MYL)
  • sanofi-aventis (ADR) (SNY)
  • Endo Pharmaceuticals (ENDP)
  • Merck KGaA

Key Financial Summary:

Key Metrics

  Buyer Target
Number of Employees 2,700 75
Revenue Per Employee 153,769.4 35,697.8
Total Revenue 103.5 0.7
Total Expenses 103.1 9.9
Other Revenue 0.0 0.0
Cost of Revenue 63.2 0.1
SG&A Expense 36.1 3.7
Research & Development 0.0 6.0
Other Operating Expense 0.0 0.0
Operating Income 0.4 -9.1
Unusual Income 0.0 0.0
LT Debt to Capital 0.02 25.18
Fwd P/E 34.66 -5.18
Fwd P/Rev 2.07 64.18
Book Value 266.4 32.1
Curr Portion of LTD/Cap Lease 0.0 1.2

Individual Company Summary

Focused

Buyer

Focused (): Healthcare > Outsourced Services > Development/Manufacturing Services > Contract Research Organizations (CRO) > Limited Service

Target

Focused (): Healthcare > Outsourced Services > Drug Delivery Technology > Oral Delivery

Business Description

Buyer

PRA International is a global contract research organization. It conducts clinical trials globally and serves the pharmaceutical and biotechnology companies to conduct clinical trials in multiple geographies. It performs an array of services across the spectrum of clinical development programs, from the filing of investigational new rug applications, and similar foreign regulatory applications, to the conduct of all phases of clinical trials, to product registration and post-marketing studies. Its global clinical development services include creating drug development and regulatory strategy plans, utilizing bioanalytical laboratory testing, executing Phase I clinical trials, performing Phase II through IV multi-center, international clinical trials, developing and analyzing integrated global clinical databases, preparing and submitting regulatory filings around the world, and managing long-term drug safety programs. On July 21, 2006, it acquired Pharma-Bio Research Metaholdings B.V.

Target

Penwest Pharmaceuticals Co. (Penwest) develops pharmaceutical products based on drug delivery technologies with a focus on products that address disorders of the nervous system. In June 2006, the United States Food and Drug Administration (FDA), approved for marketing Opana ER, an extended release formulation of oxymorphone hydrochloride that the Company developed with Endo Pharmaceuticals Inc (Endo), using its TIMERx drug delivery technology. Penwest is also developing product candidates designed for the treatment of pain, epilepsy, Parkinson?s disease and spasticity, as well as a product candidate for the treatment of edema resulting from congestive heart failure. The Company conducts its business primarily in North America.

Deal Summary

Key Ratios

  Buyer Target
Gross Margin % 41.88 85.73
Operating Margin % 5.85 -1,171.13
Quick Ratio 0.82 6.99
Current Ratio 0.98 7.23
Coverage Ratio -0.03 -0.05
Total Assets 458.9 51.4
Return on Equity % 6.61 -104.45
Return on Assets % 3.84 -65.22
Cash+ ST Inv. Per Share 1.51 1.62
Total Debt 0.1 12.0
Total Debt to Equity % 0.03 37.41
Total Debt to Tangible Equity % 0.39 41.44
Debt to Asset % 0.02 23.36

Product Summary

Sector Buyer Target
Healthcare
Biopharmaceuticals  
Cardiovascular System
The Cardiovascular System Subsector includes therapeutics that treat disorders affecting the heart and blood vessels.
  
Neurology
The Neurology Subsector includes therapeutics that treat disorders of the central nervous system, including the brain, spinal cord, and nerves.
  
Pain Management
The Pain Management Subsector includes therapeutics that treat and management pain.
  
Healthcare Services  
Support Services
The Support Services Subsector is comprised of companies that provide non-medical services for managing, enhancing, facilitating, and enabling the healthcare delivery process.
  
Outsourced Services
Development/Manufacturing Services
The Development/Manufacturing Services Subsector includes companies that provide research, development, manufacturing, sales and marketing to biopharmaceutical and medical device companies.
  
Drug Delivery Technology
The Drug Delivery Technology Subsector includes companies that develop novel delivery methods for therapeutics.
  
Technology  
Software  
Industry-Specific
Software that has functionality specific to a vertical industry.
  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Product Details

Sector Buyer Target
Healthcare
Biopharmaceuticals  
Cardiovascular System  
Heart Disorders  
Angina  
Calcium Channel Blocking Agents
Therapeutics that treat chest pains by preventing the entry of calcium into heart muscle cells.

Target Products:

  • Nifedipine XL
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in early stages of clinical research where human subject is involved.

Target Products:

  • PW2132 (Torsemide ER)
  
Vascular Disorders  
Hypertension  
Calcium Channel Blocking Agents
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle and increasing the excretion of sodium ions, potassium ions, and water through urine.

Target Products:

  • Nifedipine XL
  
Neurology  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of nervous system and mental disorders in early stages of clinical research where human subject is involved.

Target Products:

  • PW4110
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of nervous system and mental disorders in very early stages of research where no human subject is involved.

Target Products:

  • PW4153
  • PW4159
  • PW4158
  
Pain Management  
Narcotics  
Opioids
Therapeutics that treat pain by binding to certain nervous system receptors which alter both the perception of pain as well as the emotional response to pain.

Target Products:

  • Opana ER (Oxymorphone Hydrochloride Extended Release)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of pain in early stages of clinical research where human subject is involved.

Target Products:

  • PW4142 (Nalbuphine ER)
  
Healthcare Services  
Support Services  
Consulting
Services providing advice, assistance, and information to a wide range of healthcare companies, including pharmaceutical, medical devices, and health services companies.

Buyer Products:

  • Global Regulatory Affairs Group
  • Global Product Development Services
  
Outsourced Services
Development/Manufacturing Services  
Contract Research Organizations (CRO)  
Full Service
Contract Research Organizations (CROs) that conduct both preclinical and clinical studies in the development of new therapeutic products.

Buyer Products:

  • Early Development Services
  
Limited Service  
Clinical
Limited Service Contract Research Organizations that design, manage, and monitor human studies of new therapeutics. Other services include project management, patient recruitment, data management, biostatistical analysis, medical and regulatory affairs, and quality assurance.

Buyer Products:

  • PRA International Clinical Pharmacology Center
  • Global Medical And Safety Services
  • Clinical Trials Management Services
  • Sterling Synergy Systems Ltd.
  • Pharma Bio-Research
  • Drug Safety Management Services
  
Drug Delivery Technology  
Oral Delivery  
Hydrogel Based/Polymer Coated
Drug Delivery Technologies used to deliver drugs in a jelly like base which are enclosed using a polymer matrix.

Target Products:

  • SyncroDose
  • Geminex
  • TIMERx
  
Polymer Coated
Drug Delivery Technologies used to deliver drugs in a polymer based matrix to hold/enclose the drug.

Target Products:

  • Gastroretentive Drug Delivery System
  
Technology  
Software  
Industry-Specific  
Healthcare/Pharma  
Drug Development  
Clinical Trials Management
Software designed to manage the information and processes relating to clinical trials.

Buyer Products:

  • PRA Clinical Data Manager And Oracle Clinical
  • Flex DMS
  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Relationship Details

Key Competitors

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  Covance Inc. n/a 5,023.149 32.00 29.70 3.36 3.26 5.84
Pharmaceutical Product Development, Inc. n/a 4,644.765 28.49 28.15 3.51 3.52 5.51
MDS Inc. (USA) n/a 2,652.969 3.27 52.68 2.34 2.29 6.16
ICON plc (ADR) n/a 1,585.508 33.70 30.07 2.98 2.61 6.14
PAREXEL International Corporation n/a 1,252.822 33.60 27.68 1.36 1.39 6.31
Kendle International Inc. n/a 637.682 80.96 25.68 1.31 1.59 n/a
PharmaNet Development Group Inc. n/a 623.398 n/a 29.07 1.47 1.72 n/a
United American Healthcare. n/a 35.299 n/a n/a 1.95 n/a 1.46
United BioSource Corporation n/a n/a n/a n/a n/a n/a n/a
Quintiles Transnational Corp. n/a n/a n/a n/a n/a n/a n/a
INC Research, Inc. n/a n/a n/a n/a n/a n/a n/a
Target
  Johnson & Johnson n/a 190,863.999 18.04 16.24 3.34 3.16 13.68
Elan Corporation, plc (ADR) n/a 10,448.804 n/a -34.81 15.97 14.04 n/a
Biovail Corporation (USA) n/a 2,858.171 13.02 10.20 2.75 3.44 4.70
King Pharmaceuticals, Inc. n/a 2,574.611 8.36 5.85 1.25 1.23 1.90
K-V Pharmaceutical Company n/a 1,505.213 31.66 n/a 3.96 n/a 6.07
Alpharma Inc. n/a 929.815 16.08 22.14 1.36 1.29 1.93
Eurand N.V. n/a 731.542 n/a -79.52 6.39 6.35 9.57
Ligand Pharmaceuticals Inc. n/a 603.788 1.51 2.18 8.33 n/a 12.96
SkyePharma PLC (ADR) n/a 256.721 n/a -4.63 2.48 3.36 n/a
SCOLR Pharma Inc. n/a 128.925 n/a n/a 37.40 n/a 9.30
BioDelivery Sciences International, Inc. n/a 66.577 n/a -2.23 24.06 n/a n/a
Elite Pharmaceuticals, Inc. n/a 49.101 n/a -4.42 35.58 6.30 3.48
Purdue Pharma L.P. n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Dependent Suppliers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  ePlus Inc. n/a 84.375 n/a n/a 0.12 n/a 0.80
Target
  Mylan Inc. n/a 3,903.698 17.63 12.21 2.17 1.39 5.06
DRAXIS Health Inc. (USA) n/a 226.270 22.92 26.80 2.63 2.60 2.15

- Defined by the Company - Defined by Others

Key Customers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  Biomira Inc. (USA) n/a 102.885 n/a -4.29 28.30 n/a 9.91
Target
  Mylan Inc. 89.10% 3,903.698 17.63 12.21 2.17 1.39 5.06
sanofi-aventis (ADR) n/a 120,772.157 22.87 12.33 2.99 3.11 n/a
Endo Pharmaceuticals n/a 3,759.637 21.20 16.09 3.80 3.55 4.11
Merck KGaA n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Key Partners

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  Pro-Pharmaceuticals, Inc. n/a 26.984 5.72 n/a n/a n/a 76.01
Geriatric Oncology Consortium n/a n/a n/a n/a n/a n/a n/a
IntrinsiQ Data Corporation n/a n/a n/a n/a n/a n/a n/a
US Oncology, Inc. n/a n/a n/a n/a n/a n/a n/a
Target
  sanofi-aventis (ADR) n/a 120,772.157 22.87 12.33 2.99 3.11 n/a
Mylan Inc. n/a 3,903.698 17.63 12.21 2.17 1.39 5.06
Endo Pharmaceuticals n/a 3,759.637 21.20 16.09 3.80 3.55 4.11
DRAXIS Health Inc. (USA) n/a 226.270 22.92 26.80 2.63 2.60 2.15
Pharmaceutics International, Inc. n/a n/a n/a n/a n/a n/a n/a
Edison Pharmaceuticals, Inc. n/a n/a n/a n/a n/a n/a n/a
Merck KGaA n/a n/a n/a n/a n/a n/a n/a
Otsuka Pharmaceutical Co., Ltd. n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Financials

  Buyer Target Combined Entity
Income Statement
Operating Items
Revenue 381.9 3.0 384.9
Other Revenue 0.0 0.0 0.0
Total Revenue 381.9 3.0 384.9
Cost of Revenue 222.0 0.4 222.4
SG&A Expense 122.5 14.2 136.7
Depreciation & Amortization 15.1 0.0 15.1
Research & Development 0.0 23.7 23.7
Interest Expense 0.0 0.0 0.0
Other Operating Expense 0.0 0.0 0.0
Total Expenses 359.6 38.3 397.9
Operating Income 22.3 -35.3 -13.0
Non Operating Items
Interest Expense (Inc.), Net Non-Oprtng -0.7 1.8 1.0
Other, Net 0.3 0.0 0.3
Income Before Taxes 21.9 -33.5 -11.6
Income Taxes 4.3 0.0 4.3
Income After Taxes 17.6 -33.5 -15.9
Net Income - Excl. Xord. Items 17.6 -33.5 -15.9
Net Income - Incl. Xord. Items 17.6 -33.5 -15.9
Income Avail. to Common 17.6 -33.5 -15.9
Share Items
Basic Avg. Shares Outstanding 24.4 23.2 47.6
Basic EPS - Excl. Xord. Items 0.72 n/a -0.33
Basic EPS - Incl. Xord. Items 0.72 n/a -0.33
Full Dilution Adjustment 0.0 0.0 0.0
Fully Diluted Shares Outstanding 25.3 23.2 48.4
F.D. EPS - Excl. Xord. Items 0.70 n/a -0.33
F.D. EPS - Incl. Xord. Items 0.70 n/a -0.33
Balance Sheet
Assets
Cash and Equivalents 38.1 21.0 59.1
ST Investments 0.0 16.6 16.6
Accounts Receivable 107.3 0.6 107.9
Inventory 0.0 0.4 0.4
Prepayments and Advances 27.4 0.9 28.3
Other Current Assets 2.1 0.0 2.1
Current Assets 175.0 39.5 214.5
Accum D&A 0.0 0.0 0.0
PPE, Net 33.7 3.6 37.3
Goodwill & Intangibles 246.8 3.1 249.9
Other Assets 0.0 0.0 0.0
Other LT Assets 3.4 5.1 8.5
Total Assets 458.9 51.4 510.3
Liabilities
Accounts Payable 21.7 1.3 23.1
Payable/Accrued 0.0 0.0 0.0
Accrued Expenses 38.4 2.6 41.0
ST Debt 0.0 0.0 0.0
Curr Port of LTD & Cap Lease Oblg 0.0 1.2 1.2
Other (Current) Liabilities 118.3 0.3 118.6
Current Liab. 178.4 5.5 183.9
LT Debt 0.0 10.8 10.8
Capitalized Lease Obligations 0.0 0.0 0.0
Total LT Debt 0.0 10.8 10.8
Deferred Taxes 8.1 0.0 8.1
Other LT Liab. 5.9 3.0 8.9
Total Liabilities 192.5 19.3 211.8
Shareholders Equity
Common Stock 0.2 0.0 0.3
Additional Paid in Capital 163.8 220.3 384.1
Retained Earnings 85.4 -188.3 -102.9
Treasure Stock -0.2 0.0 -0.2
Other Equity 17.1 0.1 17.2
Total Equity 266.4 32.1 298.5
Total Liab. & Equity 458.9 51.4 510.3
Shares Outstanding 24.5 23.4 47.9
Cash Flow
Operating Cash Flow
CF Net Income 17.6 -33.5 -15.9
CF Depreciation 15.1 0.0 15.1
CF Deferred Taxes 0.0 0.0 0.0
Other Non-Cash Items 5.8 0.0 5.8
Change in Working Capital 6.8 4.5 11.2
Total Cash From Operating Activities 45.3 -29.0 16.2
Investing Cash Flow (not calculated)
Capital Expenditures -11.9 -2.4 -14.2
Other Investing Cash Flows -93.6 3.4 -90.2
Total Cash From Investing Activities -105.5 1.1 -104.4
Financing Cash Flow (not calculated)
Dividends Paid 0.0 0.0 0.0
Purchase Or Sale of Stock 5.6 3.5 9.1
Purchase and Retirement of Debt -0.1 12.0 11.9
Other Financing Cash Flow 2.3 -0.1 2.1
Total Cash From Financing Activities 7.7 15.4 23.1
Exchange Rate Effects 4.6 0.0 4.6
Net Change in Cash -47.9 -12.6 -60.5
Cash Taxes Paid 12.5 0.0 12.5
Cash Interest Paid 1.6 0.0 1.6